Terms: = Liver cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
1651 results:
1. Probiotic-derived silver nanoparticles target mtor/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment.
Elmetwalli A; Abdel-Monem MO; El-Far AH; Ghaith GS; Albalawi NAN; Hassan J; Ismail NF; El-Sewedy T; Alnamshan MM; ALaqeel NK; Al-Dhuayan IS; Hassan MG
Med Oncol; 2024 Apr; 41(5):106. PubMed ID: 38575697
[TBL] [Abstract] [Full Text] [Related]
2.
Miao X; Jiang P; Zhang X; Li X; Wu Z; Jiang Y; Liu H; Xie W; Li X; Shi B; Cai J; Gong W
Microbiol Spectr; 2024 May; 12(5):e0183923. PubMed ID: 38564670
[TBL] [Abstract] [Full Text] [Related]
3. The new N
Liu J; Nie W; Nie H; Yao H; Ren Y; Cao L; Qiu J; Wang M; Li X; An B; Jia X
Bioorg Chem; 2024 May; 146():107313. PubMed ID: 38554675
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of prunetrin induced G2/M cell cycle arrest and apoptosis via Akt/mtor/MAPK pathways in hepatocellular carcinoma cells.
Abusaliya A; Bhosale PB; Kim HH; Park MY; Jeong SH; Lee S; Kim GS
Biomed Pharmacother; 2024 May; 174():116483. PubMed ID: 38552440
[TBL] [Abstract] [Full Text] [Related]
5. Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells.
Chaisupasakul P; Pekthong D; Wangteeraprasert A; Kaewkong W; Somran J; Kaewpaeng N; Parhira S; Srisawang P
PLoS One; 2024; 19(3):e0300051. PubMed ID: 38527038
[TBL] [Abstract] [Full Text] [Related]
6. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract] [Full Text] [Related]
7. Evidence of promoting effects of 6:2 Cl-PFESA on hepatocellular carcinoma proliferation in humans: An ideal alternative for PFOS in terms of environmental health?
Hong J; Du K; Jin H; Chen Y; Jiang Y; Zhang W; Chen D; Zheng S; Cao L
Environ Int; 2024 Apr; 186():108582. PubMed ID: 38513556
[TBL] [Abstract] [Full Text] [Related]
8. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract] [Full Text] [Related]
9. Integrated clinical and prognostic analyses of mtor/Hippo pathway core genes in hepatocellular carcinoma.
Feng T; Chen P; Wang T; Lai C; Yao Y
J Physiol Biochem; 2024 May; 80(2):439-449. PubMed ID: 38468074
[TBL] [Abstract] [Full Text] [Related]
10. Everolimus decreases [U-
Ariaans G; Tiersma JF; Evers B; Gerding A; Waaijer SJH; Koster RA; Touw DJ; Bakker BM; Reijngoud DJ; de Jong S; Jalving M
Biomed Pharmacother; 2024 Apr; 173():116362. PubMed ID: 38432130
[TBL] [Abstract] [Full Text] [Related]
11. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.
Liu XL; Run-Hua Z; Pan JX; Li ZJ; Yu L; Li YL
Pigment Cell Melanoma Res; 2024 May; 37(3):411-425. PubMed ID: 38411373
[TBL] [Abstract] [Full Text] [Related]
12. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
[TBL] [Abstract] [Full Text] [Related]
13. TRIM29 modulates proteins involved in PTEN/AKT/mtor and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma.
Yin YT; Shi L; Wu C; Zhang MY; Li JX; Zhou YF; Wang SC; Wang HY; Mai SJ
Med Oncol; 2024 Feb; 41(3):79. PubMed ID: 38393440
[TBL] [Abstract] [Full Text] [Related]
14. Genetic loss of Nrf1 and Nrf2 leads to distinct metabolism reprogramming of HepG2 cells by opposing regulation of the PI3K-AKT-mtor signalling pathway.
Deng R; Zhu Y; Liu K; Zhang Q; Hu S; Wang M; Zhang Y
Bioorg Chem; 2024 Apr; 145():107212. PubMed ID: 38377819
[TBL] [Abstract] [Full Text] [Related]
15. Everolimus inhibits hepatoblastoma by inducing autophagy-dependent ferroptosis.
Huang H; Yan J; Xu X; Feng Y; Liu H; Liu J; Xie M; Chen L; Xiang D; Peng W; Zeng L; Zeng Y; Chen F; Zhang S; Liu Q
Drug Dev Res; 2024 Feb; 85(1):e22140. PubMed ID: 38349263
[TBL] [Abstract] [Full Text] [Related]
16. Investigation on the mechanism of the combination of eremias multiocellata and cisplatin in reducing chemoresistance of gastric cancer based on
Cheng FE; Li Z; Bai X; Jing Y; Zhang J; Shi X; Li T; Li W
Aging (Albany NY); 2024 Feb; 16(4):3386-3403. PubMed ID: 38345573
[TBL] [Abstract] [Full Text] [Related]
17. Nutrient restriction-activated Fra-2 promotes tumor progression via IGF1R in miR-15a downmodulated pancreatic ductal adenocarcinoma.
Rampioni Vinciguerra GL; Capece M; Reggiani Bonetti L; Nigita G; Calore F; Rentsch S; Magistri P; Ballarin R; Di Benedetto F; Distefano R; Cirombella R; Vecchione A; Belletti B; Baldassarre G; Lovat F; Croce CM
Signal Transduct Target Ther; 2024 Feb; 9(1):31. PubMed ID: 38342897
[TBL] [Abstract] [Full Text] [Related]
18. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mtor signaling pathway in triple negative breast cancer.
Ou X; Tan Y; Xie J; Yuan J; Deng X; Shao R; Song C; Cao X; Xie X; He R; Li Y; Tang H
Drug Resist Updat; 2024 Mar; 73():101063. PubMed ID: 38335844
[TBL] [Abstract] [Full Text] [Related]
19. MHY1485 promotes adriamycin sensitivity in HepG2 cells by inhibiting autophagy.
Guo J; Lei Y; Liu L; Wen Z; Zhang B; Fang J; Liang G; Guo Q; Peng J
Funct Integr Genomics; 2024 Feb; 24(1):22. PubMed ID: 38306005
[TBL] [Abstract] [Full Text] [Related]
20. Natural products targeting macroautophagy signaling in hepatocellular carcinoma therapy: Recent evidence and perspectives.
Chen Y; Tan X; Zhang W; Li Y; Deng X; Zeng J; Huang L; Ma X
Phytother Res; 2024 Mar; 38(3):1623-1650. PubMed ID: 38302697
[TBL] [Abstract] [Full Text] [Related]
[Next]
